Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I.

Autor:	Melhado EM; Centro Universitário Padre Albino, Faculdade de Medicina, Departamento de Neurologia, Catanduva SP, Brazil., Santos PSF; Instituto de Neurologia de Curitiba, Departamento de Neurologia, Setor de Cefaleia e Dor Orofacial, Curitiba PR, Brazil., Kaup AO; Houston Headache Clinic, Houston TX, United States.; Universidade Federal de São Paulo, Departamento de Neurologia, São Paulo SP, Brazil.; Universidade de Santo Amaro, São Paulo SP, Brazil., Costa ATNMD; Hospital Santa Marcelina, São Paulo SP, Brazil., Roesler CAP; Q2 Centro Médico de Neurologia, Depto de Neurologia, São Paulo SP, Brazil., Piovesan ÉJ; Universidade Federal do Paraná, Departamento de Clínica Médica, Disciplina de Neurologia, Curitiba PR, Brazil., Sarmento EM; Universidade Federal Fluminense, Rio de Janeiro RJ, Brazil., Theotonio GOM; Universidade Federal do Rio de Janeiro, Centro de Pesquisas, Rio de Janeiro RJ, Brazil., Campos HC; Clínica Neurológica, Belo Horizonte MG, Brazil., Fortini I; Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil., Souza JA; Universidade Federal Fluminense, Departamento de Medicina Clínica, Disciplina de Neurologia, Niterói RJ, Brazil., Maciel Júnior JA; Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Neurologia, Campinas SP, Brazil., Segundo JBA; Centro Integrado de Saúde Lineu Araújo, Ambulatório de Neurologia, Teresina PI, Brazil., Carvalho JJF; Unichristus, Curso de Medicina, Disciplina de Neurologia, Fortaleza CE, Brazil.; Hospital Geral de Fortaleza, Serviço de Neurologia, Núcleo de Cefaleias, Fortaleza CE, Brazil., Speziali JG; Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurologia, Ribeirão Preto SP, Brazil., Calia LC; Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil., Barea LM; Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Disciplina de Neurologia, Porto Alegre RS, Brazil., Queiroz LP; Universidade Federal de Santa Catarina, Hospital Universitário, Serviço de Neurologia, Florianópolis SC, Brazil., Souza MNP; Universidade de São Paulo, Hospital das Clínicas, Depto de Neurologia, São Paulo SP, Brazil., Figueiredo MRCF; Hospital Universitário Antônio Pedro, Serviço de Neurologia, Niterói RJ, Brazil., Costa MENM; Universidade Federal Fluminense, Rio de Janeiro RJ, Brazil.; Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil., Peres MFP; Hospital Israelita Albert Einstein, Departamento de Neurologia, São Paulo SP, Brazil., Jurno ME; Fundação José Bonifácio Lafayette de Andrada, Faculdade de Medicina de Barbacena, Barbacena MG, Brazil.; Fundação Hospitalar do Estado de Minas Gerais, Hospital Regional de Barbacena Dr. José Américo, Barbacena MG, Brazil., Peixoto PM; Secretaria de Estado da Saúde do Distrito Federal, Brasília DF, Brazil., Kowacs PA; Instituto de Neurologia de Curitiba, Serviço de Neurologia, Curitiba PR, Brazil.; Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Neurologia, Curitiba PR, Brazil., Rocha-Filho PAS; Universidade Federal de Pernambuco, Centro de Ciências Médicas, Área de Neuropsquiatria, Recife PE, Brazil.; Universidade de Pernambuco, Hospital Universitário Oswaldo Cruz, Ambulatório de Cefaleias, Recife PR, Brazil., Moreira Filho PF; Universidade Federal Fluminense, Hospital Universitário Antônio Pedro, Departamento de Medicina Clínica, Niterói RJ, Brazil., Silva-Neto RP; Universidade Federal do Pará, Belém PA, Brazil.; Universidade do Estado do Pará, Belém PA, Brazil., Fragoso YD; Universidade Metropolitana de Santos, Santos SP, Brazil.
Jazyk:	angličtina
Zdroj:	Arquivos de neuro-psiquiatria [Arq Neuropsiquiatr] 2022 Aug; Vol. 80 (8), pp. 845-861. Date of Electronic Publication: 2022 Oct 17.
DOI:	10.1055/s-0042-1756441
Abstrakt:	The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers. Competing Interests: AOK: speaker for Allergan, Ipsen Pharma, Merz, Onyxcann Cantera; ATNMC: speaker for Lilly, Teva, Ache, Supera, Allergan, Novartis; CAPR: speaker for Teva, Novartis, Eli Lilly, Lundbeck, Aché, Apsen, Cellera; EJP: speaker for Novartis, Allergan, Libbs, Lilly; EMS: speaker for Libbs, Allergan, Novartis, Lilly, Lundbeck, Teva; advisory board: Allergan, Libbs, Teva, Lundbeck; EMM: speaker for Teva, Eli Lilly, Allergan; advisory board: Libbs, Eli Lilly; GOMT: speaker for Eli Lilly; HCC: speaker for Allergan, Eli Lilly; JAS: speaker for Eli Lilly, Novartis, Teva; JJFC: speaker for Eli Lilly, Novartis, TEVA, Libbs; advisory board: TEVA, Novartis, Eli Lilly; JGS: speaker for Teva, Novartis, Allergan, Lilly; LCC: speaker for Allergan, Novartis, Sanofi; advisory board: Allergan; LMB: speaker for Novartis; LPQ: speaker for Eli Lilly, Allergan; advisory board: Eli Lilly, TEVA; MNPS: speaker for Lilly, Novartis, Teva, Allergan, Libbs; advisory board: Sanofi, Lilly, Libbs; MENMC: speaker for Eli Lilly, Novartis, Teva, Allergan; advisory board: Eli Lilly; MFPP: Grants from Fapesp and CNPq; personal fees from Allergan, Eurofarma, Eli Lilly, Libbs, Novartis, Pfizer, and Teva, during studies; PMP: speaker for Novartis, Teva, Eli Lilly, Libbs; advisory board: Libbs; PSFS: speaker for Teva, Novartis, Allergan, EMS, Politec; advisory board: Libbs, Lilly; PAK: fees for services to Libbs, Novartis, Allergan, Livanova, Teva; PASRF: speaker for Eli Lilly, Novartis, Allergan, Libbs; advisory board: Novartis, Eli Lilly; IF, JAMJ, JBAS, MRCFF, MEJ, PFMF, RPSN, YDF: no conflict of interests to declare. (Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu